With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

Stock index futures jumped on Tuesday, as the July retail inflation report came largely in line, but core CPI was slightly ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

Pfizer (NYSE: PFE) reported that its Phase III THRIVE-131 study of inclacumab, an experimental P-selectin inhibitor for ...

A declining stock price amid steadily rising payouts means Realty Income stock offers an above-average yield of 5.5% at ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Let’s take a closer look at a few biotech stocks poised to benefit from this resurgence. Medicus Pharma Ltd. (NASDAQ: MDCX) is an emerging biotech and life sciences company with a global footprint ...

Pfizer Inc. (NYSE:PFE)’s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with ...